Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn

Latest Articles

  • You have access
    In Vitro Inhibition of Human Aldehyde Oxidase Activity by Clinically Relevant Concentrations of Gefitinib and Erlotinib: Comparison with Select Metabolites, Molecular Docking Analysis, and Impact on Hepatic Metabolism of Zaleplon and Methotrexate
    Wee Kiat Tan, Alyssa Rui Yi Tan, Punitha Sivanandam, Ernest Jing Hui Goh, Ze Ping Yap, Nur Fazilah Saburulla, Karl Austin-Muttitt, Jonathan G.L. Mullins and Aik Jiang Lau
    Journal of Pharmacology and Experimental Therapeutics August 2020, 374 (2) 295-307; DOI: https://doi.org/10.1124/jpet.120.265249
  • You have access
    Lysophosphatidic Acid Receptor Agonism: Discovery of Potent Nonlipid Benzofuran Ethanolamine Structures
    Etienne Guillot, Jean-Christophe Le Bail, Pascal Paul, Valérie Fourgous, Pascale Briand, Michel Partiseti, Bruno Cornet, Philip Janiak and Christophe Philippo
    Journal of Pharmacology and Experimental Therapeutics August 2020, 374 (2) 283-294; DOI: https://doi.org/10.1124/jpet.120.265454
  • You have access
    3,4-Methylenedioxypyrovalerone: Neuropharmacological Impact of a Designer Stimulant of Abuse on Monoamine Transporters
    Charlotte P. Magee, Christopher L. German, Yasmeen H. Siripathane, Peter S. Curtis, David J. Anderson, Diana G. Wilkins, Glen R. Hanson and Annette E. Fleckenstein
    Journal of Pharmacology and Experimental Therapeutics August 2020, 374 (2) 273-282; DOI: https://doi.org/10.1124/jpet.119.264895
  • You have access
    Heterologous Expression and Functional Characterization of Novel CYP2C9 Variants Identified in the Alaska Native People
    Matthew G. McDonald, Lindsay M. Henderson, Sutapa Ray, Catherine K. Yeung, Amanda L. Johnson, John P. Kowalski, Helmut Hanenberg, Constanze Wiek, Kenneth E. Thummel and Allan E. Rettie
    Journal of Pharmacology and Experimental Therapeutics August 2020, 374 (2) 233-240; DOI: https://doi.org/10.1124/jpet.120.265850
  • [<sup>3</sup>H]Dopamine Uptake through the Dopamine and Norepinephrine Transporters is Decreased in the Prefrontal Cortex of Transgenic Mice Expressing HIV-1 Transactivator of Transcription Protein
    You have access
    [3H]Dopamine Uptake through the Dopamine and Norepinephrine Transporters is Decreased in the Prefrontal Cortex of Transgenic Mice Expressing HIV-1 Transactivator of Transcription Protein
    Matthew Strauss, Bernadette O’Donovan, Yizhi Ma, Ziyu Xiao, Steven Lin, Michael T. Bardo, Pavel I. Ortinski, Jay P. McLaughlin and Jun Zhu
    Journal of Pharmacology and Experimental Therapeutics August 2020, 374 (2) 241-251; DOI: https://doi.org/10.1124/jpet.120.266023
  • Open Access
    ELX-02 Generates Protein via Premature Stop Codon Read-Through without Inducing Native Stop Codon Read-Through Proteins
    Daniel K. Crawford, Iris Alroy, Neal Sharpe, Matthew M. Goddeeris and Greg Williams
    Journal of Pharmacology and Experimental Therapeutics August 2020, 374 (2) 264-272; DOI: https://doi.org/10.1124/jpet.120.265595
  • Open Access
    MK-8719, a Novel and Selective O-GlcNAcase Inhibitor That Reduces the Formation of Pathological Tau and Ameliorates Neurodegeneration in a Mouse Model of Tauopathy
    Xiaohai Wang, Wenping Li, Jacob Marcus, Michelle Pearson, Lixin Song, Karen Smith, Giuseppe Terracina, Julie Lee, Kwok-Lam Karen Hong, Sherry X. Lu, Lynn Hyde, Shu-Cheng Chen, David Kinsley, Jerry P. Melchor, Daniel J. Rubins, Xiangjun Meng, Eric Hostetler, Cyrille Sur, Lili Zhang, Joel B. Schachter, J. Fred Hess, Harold G. Selnick, David J. Vocadlo, Ernest J. McEachern, Jason M. Uslaner, Joseph L. Duffy and Sean M. Smith
    Journal of Pharmacology and Experimental Therapeutics August 2020, 374 (2) 252-263; DOI: https://doi.org/10.1124/jpet.120.266122
  • You have access
    Comparative Pharmacokinetics of Δ9-Tetrahydrocannabinol in Adolescent and Adult Male Mice
    Alexa Torrens, Valentina Vozella, Hannah Huff, Brandon McNeil, Faizy Ahmed, Andrea Ghidini, Stephen V. Mahler, Marilyn A. Huestis, Aditi Das and Daniele Piomelli
    Journal of Pharmacology and Experimental Therapeutics July 2020, 374 (1) 151-160; DOI: https://doi.org/10.1124/jpet.120.265892
  • You have access
    Evolution of the Systems Pharmacokinetics-Pharmacodynamics Model for Antibody-Drug Conjugates to Characterize Tumor Heterogeneity and In Vivo Bystander Effect
    Aman P. Singh, Gail M. Seigel, Leiming Guo, Ashwni Verma, Gloria Gao-Li Wong, Hsuan-Ping Cheng and Dhaval K. Shah
    Journal of Pharmacology and Experimental Therapeutics July 2020, 374 (1) 184-199; DOI: https://doi.org/10.1124/jpet.119.262287
  • Open Access
    Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase δ Inhibitor with Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy
    Niu Shin, Matthew Stubbs, Holly Koblish, Eddy W. Yue, Maxim Soloviev, Brent Douty, Kathy He Wang, Qian Wang, Mingming Gao, Patricia Feldman, Gengjie Yang, Leslie Hall, Michael Hansbury, Sybil O’Connor, Lynn Leffet, Robert Collins, Kamna Katiyar, Xin He, Paul Waeltz, Paul Collier, Jin Lu, Yun-Long Li, Yanlong Li, Phillip C.C. Liu, Timothy Burn, Maryanne Covington, Sharon Diamond, Dana Shuey, Alan Roberts, Swamy Yeleswaram, Greg Hollis, Brian Metcalf, Wenqing Yao, Reid Huber, Andrew Combs, Robert Newton and Peggy Scherle
    Journal of Pharmacology and Experimental Therapeutics July 2020, 374 (1) 211-222; DOI: https://doi.org/10.1124/jpet.120.265538

Pages

  • Previous
  • Next
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • …
  • 3343
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics